Loading, please wait...
.webp&w=384&q=75){kind=logo}
Verifying...
Loading, please wait...
"Wherever the art of Medicine is loved, there is also a love of Humanity."
Hippocrates
Recent research from IIT Kanpur identified a key protein that helps tumors resist colorectal cancer chemotherapy. This protein, dyskerin pseudouridine synthase 1 (DKC1), plays a major role in cancer cell survival. Ultimately, this discovery could help clinicians identify patients who require targeted therapies rather than standard treatment regimens.
In this landmark study, scientists investigated how DKC1 drives tumor progression. They found that elevated DKC1 levels allow cancer cells to bypass apoptosis, the natural self-destruction process. Consequently, these unhealthy cells can survive and multiply rapidly. Furthermore, the protein alters how cancer cells change their lipid production mechanisms, specifically by dysregulating sphingolipid biosynthesis. Therefore, the tumors can easily escape the toxic effects of standard chemotherapy drugs.
Subsequently, researchers performed detailed laboratory experiments. When they targeted and reduced DKC1 levels, tumor growth slowed down significantly. Moreover, this intervention made the cancer cells highly sensitive to chemotherapy once again. Importantly, blocking the metabolic pathways linked to DKC1 and fat production weakened cancer progression. As a result, this research provides a promising pathway to design personalized treatments for drug-resistant patients.
The collaborative research involved premier institutions like Tata Memorial Centre, King George’s Medical University, and Henry Ford Health System. Analyzing clinical data from patients, the team observed that individuals with high DKC1 expression had advanced stages of the disease. Specifically, these patients suffered from significantly poorer survival rates. Consequently, DKC1 shows great potential as a prognostic biomarker to guide customized therapeutic interventions.
Q1: What is DKC1 and how does it affect colorectal cancer?
DKC1 is a protein originally known for supporting basic cellular growth and ageing. In colorectal cancer, high levels of DKC1 help tumor cells bypass natural self-destruction and resist chemotherapy by altering sphingolipid production.
Q2: How can this discovery change colorectal cancer treatment?
This discovery allows DKC1 to serve as a biomarker. Consequently, doctors can identify patients likely to resist standard chemotherapy and instead recommend targeted therapies early in the treatment process.
Q3: Which institutions collaborated on this study?
The research was spearheaded by IIT Kanpur under Prof. Bushra Ateeq. In addition, the team collaborated with Tata Memorial Centre, King George’s Medical University, and the Henry Ford Health System.
Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice or replace professional judgment. Refer to the latest local and national guidelines for clinical practice.
References
Link will be sent via SMS to your number.
IIT Kanpur researchers discovered that the DKC1 protein enables colorectal cancer cells to survive chemotherapy, offering a new biomarker for targeted thera...
4 weeks back
The Phase II RECLAIM trial explores a novel rescue strategy for metastatic NSCLC patients who progressed on anti-PD-1 therapy. By combining subablative radiotherapy with ipilimumab and nivolumab, researchers evaluated efficacy in patients with low or negative PD-L1 expression, offering a potential new path forward.
Today
A study on 294 women after the Kahramanmaras earthquake shows that death distress, especially death depression, significantly influences fertility intentions. Key factors include age, income, and trauma experience, highlighting the need for mental health support in post-disaster care.
Today
A multicohort study across 33 countries reveals that loneliness significantly increases the risk of cardiometabolic disease, particularly multimorbidity. The study highlights the synergistic impact of unhealthy lifestyles and low socioeconomic status on cardiovascular health in aging populations.
Today
A new study in rats suggests that combining intra-articular dimethyl itaconate with systemic vancomycin significantly reduces bone loss, inflammation, and bacterial load in periprosthetic joint infections, offering a promising dual-action therapeutic strategy for future clinical consideration.
Today
Recent research explores low-temperature pyrolysis as a tool to reduce PFAS in sewage sludge. While it lowers total concentrations, stable compounds like PFOS and significant leaching under acidic conditions suggest continued risks for food safety and public health.
Today